US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Silexion Therapeutics Corp

1.00

+0.01521.54%

Post-market: 0.9900-0.0100-1.00%19:43 EDT

Volume:323.82K

Turnover:326.38K

Market Cap:8.69M

PE:-7.41

High:1.06

Open:1.00

Low:0.9561

Close:0.9848

Loading ...

Overview Company News Filings

BRIEF-Silexion Therapeutics Announces Collaboration With Global Therapeutics Leader Catalent On Advanced Sirna Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Announces Collaboration With Global Therapeutics Leader Catalent on Advanced Sirna Formulation Development & Clinical Manufacturing Activities

THOMSON REUTERS

Silexion Therapeutics announces expanded development plan for SIL204

BRIEF-Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204

Silexion Therapeutics Corp - to Conduct Additional Toxicology and Pharmacodynamic Studies in 2025

THOMSON REUTERS

Silexion Therapeutics Corp - Unveils Expanded Development Plan for Sil204 - SEC Filing

THOMSON REUTERS

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion announces completion of expanded development plan for SIL204

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Is Maintained at Buy by Maxim Group

Silexion Therapeutics 2024 Net Income $(16.5)M Vs $(5.1)M In 2023

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Corp: Anticipates Sharing Initial Results From Sil-204 Study in March 2025

THOMSON REUTERS

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Dow Jumps Over 100 Points; Tesla Earnings Miss Views

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SLXN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1,"timestamp":1746129600000,"preClose":0.9848,"halted":0,"volume":323824,"hourTrading":{"tag":"盘后","latestPrice":0.99,"preClose":1,"latestTime":"19:43 EDT","volume":2028,"amount":2009.1055,"timestamp":1746143020518},"delay":0,"floatShares":5231700,"shares":8692392,"eps":-0.135024,"marketStatus":"Closed","change":0.0152,"latestTime":"05-01 16:00:00 EDT","open":1,"high":1.06,"low":0.9561,"amount":326377.0607984,"amplitude":0.105504,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.135024,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746172800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":0.9848,"preHourTrading":{"tag":"盘前","latestPrice":0.99,"preClose":0.9848,"latestTime":"09:25 EDT","volume":7114,"amount":7079.3597998000005,"timestamp":1746105913262},"postHourTrading":{"tag":"盘后","latestPrice":0.99,"preClose":1,"latestTime":"19:43 EDT","volume":2028,"amount":2009.1055,"timestamp":1746143020518},"volumeRatio":0.52448},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5231700,"roa":"-193.54%","roe":"--","lyrEps":0.042916,"volumeRatio":0.52448,"shares":8692392,"dividePrice":0,"high":1.06,"amplitude":0.105504,"preClose":0.9848,"low":0.9561,"week52Low":0.575,"pbRate":"-2.18","week52High":122.0184,"institutionHeld":0,"latestPrice":1,"eps":-0.135024,"divideRate":0,"volume":323824,"delay":0,"ttmEps":-0.135024,"open":1,"prevYearClose":2.01,"prevWeekClose":0.9343,"prevMonthClose":0.9848,"prevQuarterClose":1.1,"fiveDayClose":0.93,"twentyDayClose":0.992,"sixtyDayClose":1.25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529685793","title":"BRIEF-Silexion Therapeutics Announces Collaboration With Global Therapeutics Leader Catalent On Advanced Sirna Formulation Development & Clinical Manufacturing Activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2529685793","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529685793?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:20","pubTimestamp":1745414459,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Announces Collaboration With Global Therapeutics Leader Catalent On Advanced Sirna Formulation Development & Clinical Manufacturing ActivitiesApril 23 (Reuters) - Silexion ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA1ZNHJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2529685428","title":"Silexion Therapeutics Announces Collaboration With Global Therapeutics Leader Catalent on Advanced Sirna Formulation Development & Clinical Manufacturing Activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2529685428","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529685428?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:20","pubTimestamp":1745414400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA1ZNHJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2522794465","title":"Silexion Therapeutics announces expanded development plan for SIL204","url":"https://stock-news.laohu8.com/highlight/detail?id=2522794465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522794465?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:41","pubTimestamp":1743165681,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates syste...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-announces-expanded-development-plan-for-sil204?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-announces-expanded-development-plan-for-sil204?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN","BK4139","LENZ"],"gpt_icon":0},{"id":"2522576041","title":"BRIEF-Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204","url":"https://stock-news.laohu8.com/highlight/detail?id=2522576041","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522576041?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:34","pubTimestamp":1743165292,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204March 28  - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS CORP - UNVEILS EXPANDED DEVELOPMENT PLAN FOR SIL204 - SEC FILINGSILEXION THERAPEUTICS CORP - TO CONDUCT ADDITIONAL TOXICOLOGY AND PHARMACODYNAMIC STUDIES IN 2025Further company coverage: SLXN.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2522789576","title":"Silexion Therapeutics Corp - to Conduct Additional Toxicology and Pharmacodynamic Studies in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522789576","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522789576?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:32","pubTimestamp":1743165165,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0Y7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2522576223","title":"Silexion Therapeutics Corp - Unveils Expanded Development Plan for Sil204 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522576223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522576223?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:32","pubTimestamp":1743165165,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2522574521","title":"Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2522574521","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522574521?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:30","pubTimestamp":1743165000,"startTime":"0","endTime":"0","summary":"Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and previous promising clinical data from its first-generation product; Company shares its strategic roadmap for SIL204’s clinical development including plans to initiate human trials in H1 2026. The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that systemic administration of SIL204 significantly inhibits tumor growth in clinically relevant orthotopic models of pancreatic cancer. This dual-route approach is designed to address the aggressive nature of KRAS-driven cancers, which are characterized by high mortality and limited treatment options.The expanded development plan is supported by compelling data from both Silexion's clinical and preclinical programs. TheCompany's first-generation product, siG12DLoder, demonstrated an over","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silexion-therapeutics-unveils-innovative-expanded-123000831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","SLXN","SLXNW"],"gpt_icon":0},{"id":"2521865652","title":"Silexion announces completion of expanded development plan for SIL204","url":"https://stock-news.laohu8.com/highlight/detail?id=2521865652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521865652?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:40","pubTimestamp":1742560853,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-announces-completion-of-expanded-development-plan-for-sil204?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-announces-completion-of-expanded-development-plan-for-sil204?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2521286971","title":"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2521286971","media":"GlobeNewswire","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521286971?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:30","pubTimestamp":1742560200,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the Presentation. Grand Cayman, Cayman Islands, March 21, 2025  -- Silexion Therapeutics Corp. , a clinical-stage biotechnology company pioneering RNA interference  therapies for KRAS-driven cancers,today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company’s management will be presenting at the upcoming Cancer Advocacy Group of Louisiana  NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA.The newly completed strategic plan builds upon Silexion's recent promising preclinical data and is designed to maximize SIL-204's potential across multiple delivery approaches to address ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silexion-therapeutics-announces-completion-innovative-123000352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SLXN","LENZ","SLXNW"],"gpt_icon":0},{"id":"2520463053","title":"Silexion Therapeutics Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2520463053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520463053?lang=en_us&edition=fundamental","pubTime":"2025-03-20 23:11","pubTimestamp":1742483460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLXN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 11:11 ET (15:11 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","LENZ"],"gpt_icon":0},{"id":"2520326879","title":"Silexion Therapeutics 2024 Net Income $(16.5)M Vs  $(5.1)M In 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2520326879","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520326879?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:32","pubTimestamp":1742329938,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics 2024 Net Income $(16.5)M Vs  $(5.1)M In 2023","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44385979/silexion-therapeutics-2024-net-income-16-5-m-vs-5-1-m-in-2023","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","SLXN"],"gpt_icon":0},{"id":"2520834932","title":"Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520834932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520834932?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:29","pubTimestamp":1742329776,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nTUAC72RGR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2520693218","title":"Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520693218","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520693218?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:29","pubTimestamp":1742329740,"startTime":"0","endTime":"0","summary":"Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse mod","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/18/3044999/0/en/Silexion-Therapeutics-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ORR","BK4139","SLXN"],"gpt_icon":0},{"id":"2520652560","title":"PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2520652560","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520652560?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:15","pubTimestamp":1742213700,"startTime":"0","endTime":"0","summary":"Silexion's Groundbreaking Orthotopic Model Data and the Potential Expansion of its Development Plan Position SIL204 as Potential Transformative Therapy; Wall Street Maintains Buy Rating and $9 Price Target representing a signifcant premium of almost +600% over current prices; Silexion's new expanded development plan expected to be completed shortly; Precision Oncology M&A Market has heated up in recent years with a series of Multi-Billion Dollar Acquisitions in the field. NEW YORK, March 17, 2025----PESG Research releases a report covering Silexion Therapeutics’ * latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SIL204 therapeutic candidate. The latest findings represents a critical milestone in the fight against KRAS-driven cancers, particularly pancreatic cancer, showcasing significant potential in addressing one of oncology's most challenging targets.Maxim Group has maintained its analysis of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pesg-report-silexion-therapeutics-breakthrough-121500022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLXN","SLXNW","BK4139","LENZ"],"gpt_icon":0},{"id":"2517914907","title":"Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2517914907","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517914907?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:30","pubTimestamp":1741181400,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic Cance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/05/3037405/0/en/Silexion-Therapeutics-Reports-Groundbreaking-Positive-Initial-Data-from-Systemic-Administration-of-SIL204-in-Orthotopic-Pancreatic-Cancer-Models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SLXN","BK4139"],"gpt_icon":0},{"id":"2516636126","title":"PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational","url":"https://stock-news.laohu8.com/highlight/detail?id=2516636126","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516636126?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:30","pubTimestamp":1741008600,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic cancer model data, which, if positive, could validate systemic efficacy against metastatic disease for the first time. Reportedly, Maxim Group maintains a $9 price target and strong buy rating, citing the company's growing clinical trajectory and RNAi platform validation. With a data readout expected this month, this could be a major catalyst for the company, as interest for innovative KRAS-targeting therapies continues to rise. The ability to target both primary and metastatic pancreatic cancer via systemic administration would represent a major breakthrough, as Silexion has not previously demonstrated this effect in metastatic models. If the orthotopic model results show significant impact on metastases, this could mark a critical validation step, potentially differentiating SIL-204 from existing KRAS-targeting approaches and opening the door to expanded clinical applications.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pesg-industry-anticipation-rises-silexion-133000441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SLXN","SLXNW","LENZ"],"gpt_icon":0},{"id":"2514091970","title":"Silexion Therapeutics Corp:  Anticipates Sharing Initial Results From Sil-204 Study in March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514091970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514091970?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:30","pubTimestamp":1740490257,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2514094309","title":"Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204","url":"https://stock-news.laohu8.com/highlight/detail?id=2514094309","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514094309?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:30","pubTimestamp":1740490200,"startTime":"0","endTime":"0","summary":"Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks. Grand Cayman, Cayman Islands, Feb. 25, 2025  -- Silexion Therapeutics Corp.  , a clinical-stage biotechnology company pioneering RNA interference  therapies for KRAS-driven cancers, today announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This milestone represents the first systematic evaluation of SIL-204 administered subcutaneously in clinically relevant pancreatic cancer models.The study specifically evaluated two critical aspects of SIL-204's potential therapeutic profile:. SIL-204's ability to reduce primary tumor growth when administered systemically in orthotopic pancreatic cancer models, where human tumor cells are implanted directly into the pancreas. \"Completing this initial study in orthotopic models represents a significant milestone in our","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silexion-therapeutics-announces-completion-initial-133000462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SIL","SLXN","BK4139","LENZ","SLXNW"],"gpt_icon":0},{"id":"2507249406","title":"Dow Jumps Over 100 Points; Tesla Earnings Miss Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2507249406","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507249406?lang=en_us&edition=fundamental","pubTime":"2025-01-30 23:03","pubTimestamp":1738249415,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/01/43340053/dow-jumps-over-100-points-tesla-earnings-miss-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLA","TECX","CRGX","ATHE","PCOM","SLXN","CLEU","AMOD","TSLL"],"gpt_icon":1},{"id":"2507661799","title":"Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2507661799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507661799?lang=en_us&edition=fundamental","pubTime":"2025-01-30 06:30","pubTimestamp":1738189800,"startTime":"0","endTime":"0","summary":"Cayman Islands, January 29, 2025 --Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017648/0/en/Silexion-Therapeutics-Announces-Exercise-of-Warrants-for-3-3-Million-Gross-Proceeds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN","LENZ"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":64,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1730520000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2025-04-30","current":-0.46057,"percent":1,"low":-0.478123,"twenty":-0.472146,"median":-0.46318,"eighty":-0.461614,"high":-0.46057,"avg":-0.467291,"sd":0.007733,"marketCap":7573153},"quantilePoints":[{"date":"2025-04-30","current":-0.46057,"twenty":-0.472146,"median":-0.46318,"eighty":-0.461614,"marketCap":7573153}],"updateTime":1746145340697}}}